GLP-1 medications like semaglutide and tirzepatide can cause lean mass loss, but protein intake and resistance training change that outcome significantly. A clinical primer.
A 2026 meta-analysis of 41 RCTs clarifies cardiovascular and prostate cancer risk from TRT. Here is what the evidence actually shows, and who should be cautious.
The triglyceride-to-HDL ratio is a simple calculation hidden in your existing labs that flags insulin resistance before LDL ever will. This primer explains the thresholds and what to do next.
TRT can accelerate hair loss in genetically predisposed men via DHT conversion. Learn who is at risk, how the mechanism works, and what your options are.
Peter Attia argues optimization differs from risk reduction. For TRT, the line depends on the patient. This primer maps the clinical evidence for both categories.
BPC-157 peptide therapy shows preclinical promise for tissue repair and pain relief. Learn what the evidence actually says, realistic expectations, and safety context for men.
Estradiol is not just a female hormone. Learn how it works alongside testosterone in men, what imbalance feels like, and when estrogen management on TRT is warranted.
Testosterone raises red blood cell count. Learn why hematocrit climbs on TRT, who faces the highest risk, and how clinicians monitor and manage it safely.
A physician-reviewed comparison of semaglutide and tirzepatide for weight loss, covering how each works, side effects, cardiovascular data, and who fits each drug best.
Start with your $49 lab panel — know your numbers and take the first step toward peak performance.
Order $49 Labs